Regulators in Europe have again asked Boehringer Ingelheim, the manufacturer of the blood thinner Pradaxa, to update the drug’s label with additional information regarding Pradaxa bleeding side effects. According to the European Medicines Agency (EMA), the new guidance should include more specific information on when Pradaxa must not be used, ...
Johnson & Johnson and its Ethicon unit are again coming under scrutiny for the way it marketed its Gynecare ProLift transvaginal mesh product. According to a new report from Bloomberg News, Johnson & Johnson continued marketing the Gynecare ProLift device for months after it received a warning from the ...
In a joint statement, the American Society of Clinical Oncology and the American Association for Cancer Research have called on the federal government to move quickly to regulate e-cigarettes and increase research on their health effects.
These leading research and treatment organizations asked the Food and Drug Administration (FDA) to make ...
An advisory panel for the U.S. Food & Drug Administration (FDA) began a highly-anticipated meeting yesterday to discuss the safety of metal-on-metal hip implants. Among other things, the panel of outside experts is being asked to make recommendations regarding the best practices for monitoring patients with metal-on-metal hip replacements. ...
The Food and Drug Administration (FDA) is convening a meeting starting today to help decide the future of metal-on-metal hip implants following high-profile recalls and mounting questions about their overall safety.
Recent revelations about Nexium have uncovered kidney side effects in one of the most frequently prescribed treatments for excess stomach acid. Nexium is the brand name for esomeprazole, manufactured by Astra Zeneca. Nexium conditions such as gastroesophageal reflux or Zollinger-Ellison … Continue reading →
Nexium, Prilosec and Prevacid are part of a class of medications known as proton pump inhibitors (PPIs). They are used to relieve heartburn and acid reflux by lowering the amount of acid produced by the stomach. Recent studies suggest that … Continue reading →
Two studies published this year evaluated the risk of kidney damage associated with proton pump inhibitors (PPIs). PPIs, which treat heartburn and acid reflux by lowering the amount of stomach acid produced, include Prilosec, Nexium and Prevacid. The studies suggest … Continue reading →
New research suggests that the use of certain drugs for gastric reflux or peptic ulcers creates an increased risk for dementia in elderly patients. The class of drugs—proton pump inhibitors (PPIs)—includes Prevacid (lansoprazole), Nexium (esomeprazole), and Prilosec (omeprazole), HealthDay reports.
Researchers say repeated use certain drugs for gastric reflux or peptic ulcers is linked to a higher risk for dementia among patients in Germany. The class of drugs—proton pump inhibitors (PPIs)—includes Prevacid (lansoprazole), manufactured by Novartis, Nexium (esomeprazole) and Prilosec … Continue reading →
Proton pump inhibitors (PPIs)—widely used heartburn medicines—may increase the risk for kidney disease. PPIs are sold under brand names, including Nexium, Prevacid and Prilosec, in both prescription and over-the-counter formulas. Proton pump inhibitors (PPIs) greatly reduce the amount of acid … Continue reading →
A data-mining study published on June 10 in PLOS One shows that people who take proton pump inhibitor drugs for gastroesophageal reflux disease (GERD) are at increased risk for heart attacks. The study evaluated data for 2.9 million patients … Continue reading →
Some drugs widely used to control stomach acid may increase the risk of a serious vitamin deficiency, a new study suggests. A research team found that people who were diagnosed with vitamin B12 deficiency were more likely to be taking … Continue reading →
A retrospective study of kidney transplant patients found that those taking Proton Pump Inhibitor (PPI) drugs in conjunction with another drug in the year after their surgery were more likely to experience rejection. According to a report at RenalandUrologyNews.com on … Continue reading →
Proton Pump Inhibitors (PPIs) such as Prilosec, Aciphex, Prevacid, and Protonix, raise infection risks in cirrhosis patients, according to a new study that found the risk for serious infections affects patients with decompensated cirrhosis. PPI users suffer from a 66 … Continue reading →